Hematologic malignacy
Conditions
Interventions
presence of PRCA:Nil
absence of PRCA:Nil
Sponsors
The First Affiliated Hospital of Medical College of Zhejiang University
Eligibility
Sex/Gender
All
Age
15 Years to 67 Years
Inclusion criteria
Inclusion criteria: 1. The subjects or their legal representatives signed the informed consent before the clinical study. 2. Women of childbearing age were negative in pregnancy test within 14 days before the administration of the test drug. 3. Subjects aged 15-67 years. 4. Patients with malignant hematological diseases received allogeneic peripheral blood stem cell transplantation with major ABO incompatible blood groups. 5. Subjects with ECoG score of 0-2. 6. Subjects without major organ dysfunction.
Exclusion criteria
Exclusion criteria: 1. Patients with severe liver and kidney function (alanine aminotransferase > 2.5 times of the upper normal limit, serum creatinine > 1.5 times of the upper normal limit), cardiopulmonary dysfunction (cardiac function NYHA III / IV, cardiac ejection fraction 2; 5. Patients with secondary tumor; 6. Patients who cannot independently choose to enter or exit clinical trials due to serious central nervous system disease or mental disease.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| cumulative incidence of PRCA; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;leukemia-free survival;cumulative replase rate;nonreplase mortality;the incidence of acute GVHD and chronic GVHD; | — |
Countries
China
Contacts
Public ContactHuang he
The First Affiliated Hospital of Medical College of Zhejiang University
Outcome results
None listed